Markers of the acute phase response in cardiovascular disease: An update

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 11, 2001, Pages 1054-1064

  Whicher, J ^a   Rifai, N ^a   Biasucci, L M ^a  

^a NONE   (United Kingdom)

Author keywords

Acute phase response; Atherosclerosis; C reactive protein; Cardiovascular disease; Inflammation; Serum amyloid A protein

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ATORVASTATIN; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ACUTE DISEASE; ACUTE PHASE RESPONSE; ADULT; ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INFLAMMATORY CELL; KNOCKOUT MOUSE; LABORATORY TEST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SENSITIVITY AND SPECIFICITY; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ACUTE-PHASE REACTION; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; MONITORING, PHYSIOLOGIC; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0035210155     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.171     Document Type: Article

References (95)

1. Inflammation, the acute phase response and atherosclerosis
2. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
3. Elevation of C-reactive protein in "active" coronary artery disease
4. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
5. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
6. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
7. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Fragmin during instability in coronary artery disease
8. C-Reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. Thrombolysis in myocardial infarction
9. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris
10. Elevated levels of IL-6 in unstable angina
11. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction
12. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
13. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis. CAPTURE Investigators. Chimeric c7E3 Antiplatelet Therapy in Unstable angina REfractory to standard treatment trial
14. Independent prognostic value of elevated C-reactive protein in unstable angina
15. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
16. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy
17. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
18. Elevation of tumour necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction
19. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
20. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction
21. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment
22. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction
23. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
24. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
25. C-reactive protein (CRP) predicts risk of coronary heart disease (CHD) in healthy middle-aged men: Results from the MONICA-Augsburg cohort study, 1984/85-1992
26. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: Results from the Cardiovascular Health Study and the Rural Health Promotion Project
27. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
28. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men
29. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Augsburg Cohort Study, 1984 to 1992
30. Fibrin D-dimer, C-reactive protein and risk of ischaemic heart disease: The Speedwell study
31. Helicobacter pylori infection, C-reactive protein, and risk for myocardial infarction: A prospective study
32. Infections, inflammation, and the risk of coronary heart disease
33. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
34. C-Reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men
35. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
36. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
37. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
38. C-reactive protein and risks of myocardial infarction, stroke and death in an elderly cohort
39. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
40. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening
41. The relationship of C-reactive protein to the incidence of thromboembolic stroke
42. C-reactive protein and incident myocardial infarction in Japanese American men
43. Inflammation markers and coronary heart disease
44. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects
45. C-reactive protein and its relationship to cardivascular risk factors: A population-based cross sectional study
46. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons
47. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
48. Clinical efficacy of an automated high sensitivity C-reactive protein assay
49. The association of plasma IL-6 levels with functional disability in community-dwelling elderly
50. Complement and atherogenesis binding of CRP to degraded, nonoxidised LDL enhances complement activation
51. C-reactive protein induces human peripheral blood monocytes to synthesise tissue factor
52. Direct proinflammatory effect of C-reactive protein on human endothelial cells
53. C-reactive protein-mediated low density lipoprotein uptake by macrophages
54. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina
55. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
56. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events
57. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina
58. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
59. Long-term effects of pravastatin on plasma concentration of C-reactive protein
60. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
61. Associations between change in C-reactive protein and serum lipids during statin treatment
62. Effect of hydroxymethyl glutaryl coenzyme a reductasae inhibitor therapy on high sensitive C-reactive protein levels
63. Rapid reduction in C-reacticle protein with cerivastatin among 785 patients with primary hypercholesterolemia
64. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
65. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
66. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical athersclerosis in healthy, middle aged women
67. Elevated C-reactive protein levels in overweight and obese adults
68. C-reactive protein concentration in children: Relationship to adiposity and other cardiovascular risk factors
69. Adipose tissue as an endocrine and paracrine organ
70. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid
71. The acute phase response in patients receiving subcutaneous IL-6
72. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue
73. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Athersclerosis Study
74. Body mass index, diabetes, and C-reactive protein among U.S. adults
75. Raised C-reactive protein levels in serum from smokers
76. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
77. Oral contraceptive use is associated with a systemic acute phase response
78. Hormone replacement therapy and increased plasma concentration of C-reactive protein
79. Effect of postmenopausal hormones on inflammation-sensitive proteins
80. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in potmenopausal women
81. Immunoradiomatric assay of circulating C-reactive protein: Age-related values in the adult general population
82. Solid phase radioimmunoassays for C-reactive protein
83. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein
84. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications
85. High sensitivity C-reactive protein: Biological variations and reference limits
86. Biological variation of acute phase proteins
87. Comparative study of C-reactive protein and serum amyloid A protein in experimental inflammation
88. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults
89. Absence of diurnal variation of C-reactive protein levels in healthy human subjects
90. Evaluation of four automated high sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications
91. Evaluation of nine automated high sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications
92. Analytical evaluation of particle enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum
93. New international reference preparation for proteins in human serum (RPPHS)
94. Clinical use of CRP for prognostic stratification of patients with ischemic heart disease